Short-term Acipimox decreases the ability of plasma from type 2 diabetic patients and healthy subjects to stimulate cellular cholesterol efflux: A potentially adverse effect on reverse cholesterol transport

Diabetic Medicine

Volumn 18, Issue 6, 2001, Pages 509-513

  Dullaart, Robin P F ^a   Van Tol, A ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Acipimox; Cellular cholesterol efflux; High density lipoproteins; Phospholipid transfer protein; Pre ; Type 2 diabetes mellitus

Indexed keywords

ACIPIMOX; APOLIPOPROTEIN A1; FATTY ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPID TRANSFER PROTEIN; TRIACYLGLYCEROL;

ANIMAL CELL; ARTICLE; ATHEROGENESIS; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; CONTROLLED STUDY; DYSLIPIDEMIA; FATTY ACID BLOOD LEVEL; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT; SHORT COURSE THERAPY; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTILIPEMIC AGENTS; APOLIPOPROTEIN A-I; BODY MASS INDEX; CARRIER PROTEINS; CHOLESTEROL; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; FATTY ACIDS, NONESTERIFIED; HIGH-DENSITY LIPOPROTEINS, PRE-BETA; HUMANS; LIPOPROTEINS, HDL; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PHOSPHOLIPID TRANSFER PROTEINS; PYRAZINES; RATS; REFERENCE VALUES; TUMOR CELLS, CULTURED;

EID: 0034897227     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.2001.00507.x     Document Type: Article

References (27)

1. High-density lipoprotein - The clinical implications of recent studies
2. Cholesteryl ester transfer protein, reverse cholesterol transport and atherosclerosis
3. Molecular physiology of reverse cholesterol transport
4. Cell cholesterol efflux: Integration of old and new insights provides new insights
5. The ABC's of cholesterol efflux
6. Early incorporation of cell-derived cholesterol into pre-β-migrating high-density lipoprotein
7. 1-HDL
8. Human plasma phospholipid transfer protein causes high density lipoprotein conversion
9. Human plasma phospholipid transfer protein increases the anti-atherogenic potential of high density lipoproteins in transgenic mice
10. Phospholipid transfer protein enhances removal of cellular cholesterol and phospholipids by high-density lipoprotein apolipoproteins
11. A cell culture system for screening human serum for ability to promote cellular cholesterol efflux. Relations between serum components and efflux, esterification and transfer
12. Cholesterol efflux from Fu5AH hepatoma cells induced by plasma of subjects with or without coronary artery disease and non-insulin dependent diabetes: Importance of LpA-I:A-II particles and phospholipid transfer assay
13. Plasma phospholipid transfer protein activity is lowered by 24-h insulin infusion and Acipimox administration. Blunted response to insulin in Type 2 diabetic patients
14. Definition diagnosis and classification of diabetes mellitus and its complications. Part I: Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation
15. Influence of insulin sensitivity and the TaqIB cholesteryl ester transfer protein gene polymorphism on plasma lecithin: Cholesterol acyltransferase and lipid transfer protein activities and their response to hyperinsulinemia in non-diabetic men
16. Interconversion of prebeta-migrating lipoproteins containing apolipoprotein AI and HDL
17. Presence and formation of 'free apolipoprotein A-I-like' particles in human plasma
18. Different locations of cholesteryl ester transfer protein and phospholipid transfer protein activities in plasma
19. Pronounced blood glucose-lowering effect of the antilipolytic drug acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period
20. A double blind study of the effect of Acipimox on serum lipids, blood glucose control and insulin action in non-obese patients with Type 2 diabetes mellitus
21. Improvement of lipoprotein lipid composition in Type II diabetic patients with concomitant hyperlipoproteinemia by Acipimox treatment
22. Long-term effects of a sustained-release preparation of Acipimox on dyslipidemia and glucose metabolism in non-insulin-dependent diabetes mellitus
23. Reduced triglyceridemia and increased high density lipoprotein cholesterol levels after treatment with acipimox, a new inhibitor of lipolysis
24. Effects of acipimox on serum lipids, lipoproteins, and lipolytic enzymes in hypertriglyceridemia
25. Effects of Acipimox on haemorheology and plasma lipoproteins in patients with mixed hyperlipoproteinaemia
26. Hypertriglyceridemia as a cardiovascular risk factor
27. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterolfed rabbit